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Abstract 
Background: Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotro-
pium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from 
a UK National Health Service (NHS) perspective.
Methods: A linked-equation model was implemented to estimate COPD progression, associated healthcare costs, 
exacerbations rates, life years (LY) and quality-adjusted LY (QALYs). Statistical risk equations for endpoints and resource 
use were derived from the ECLIPSE and TORCH studies, respectively. Treatment effects [mean (standard error)] at 
12 weeks on forced expiratory volume in 1 s and St George’s Respiratory Questionnaire score were obtained from the 
intention-to-treat populations of two head-to-head studies [GSK study identifiers 201316 (NCT02207829) and 201315 
(NCT02236611)] which compared UMEC 62.5 mcg with TIO 18 mcg and UMEC 62.5 mcg with GLY 50 mcg, respec-
tively. Treatment costs reflect UK list prices (2016) and NHS unit costs; UMEC and GLY prices being equal and less than 
TIO. A lifetime horizon, discounted costs and effects at 3.5% were used. Sensitivity analyses were performed to evalu-
ate the robustness of variations in input parameters and assumptions in the model.
Results: Over a lifetime horizon, UMEC was predicted to increase LYs (+ 0.195; 95% confidence interval [CI]: 0.069, 
0.356) and QALYs (+ 0.118; 95% CI: 0.055, 0.191) and reduce the number of annual exacerbations (− 0.053; 95% CI: 
− 0.171, 0.028) compared with TIO, with incremental cost savings of £460/patient (95% CI: − £645, − £240). Compared 
with GLY, UMEC increased LYs (+ 0.124; 95% CI: 0.015, 0.281) and QALYs (+ 0.101; 95% CI: 0.043, 0.179) and reduced 
annual exacerbation (− 0.033; 95% CI: − 0.135, 0.017) at an additional cost of £132/patient (95% CI: £12, £330), result-
ing in an incremental cost-effectiveness ratio of £1310/QALY (95% CI: £284, £2060). Similar results were observed in 
alternative time horizons and additional sensitivity analyses.
Conclusions: For treatment of patients with COPD in the UK over a lifetime horizon, treatment with UMEC dominates 
treatment with TIO, providing both improved health outcomes and cost savings. In comparison with GLY, treatment 
with UMEC achieved improved health outcomes but was associated with a higher cost.
Trial registration 201316, NCT02207829; 201315, NCT02236611
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Background
Chronic obstructive pulmonary disease (COPD) is an 
irreversible and progressive disease characterised by per-
sistent airflow limitation [1, 2]. COPD presents a sub-
stantial burden to global public health [3, 4], representing 
one of the leading causes of hospitalisations and emer-
gency room (ER) visits [3], as well as a leading cause of 
death worldwide (approximately 3.2 million deaths were 
attributed to COPD in 2015) [5]. The disease and asso-
ciated comorbidities contribute significantly to health-
care costs [3, 4], indeed, the financial burden of COPD 
inevitably correlates with the severity of the disease, with 
hospital stays accounting for a substantial proportion of 
the costs [6–8]. In the UK, direct medical costs associ-
ated with COPD have been estimated at £1.9 billion per 
year [9].
The benefits of appropriate pharmacological therapy 
in COPD in decreasing symptoms, reducing the need 
for rescue therapy, decreasing the frequency and sever-
ity of exacerbations, and improving health-related qual-
ity of life (HRQoL), are well recognised and summarised 
along with treatment recommendations in the annually 
updated Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) strategic document [2]. Currently, the 
recommendation for pharmacological treatment of most 
patients with COPD is bronchodilator monotherapy or 
dual therapy with long-acting muscarinic antagonists 
(LAMAs) and long-acting β2-agonists (LABAs), depend-
ing on disease burden and exacerbation history [2]. These 
recommendations reflect the central role of broncho-
dilators in treating COPD [10, 11]. In addition, LAMAs 
have been reported to be more effective than LABAs in 
reducing the rate of exacerbations and reducing the time 
to a first moderate or severe exacerbation in patients with 
moderate-to-very severe COPD [12, 13].
Umeclidinium 62.5  mcg (UMEC) is a once-daily 
LAMA delivered via a novel dry-powder inhaler 
(Ellipta, GlaxoSmithKline, Hertfordshire, UK), which 
was approved for maintenance treatment of COPD in 
the UK in 2014 [14], and is currently approved in multi-
ple regions worldwide, including the United States [15], 
the European Union [16] and Japan [17]. Several stud-
ies have reported the efficacy of UMEC monotherapy 
versus placebo in terms of improved lung function and 
other outcomes in patients with COPD [18–20]. Stud-
ies have also compared the efficacy of UMEC with that 
of the other once-daily dry-powder inhaler LAMAs tio-
tropium 18  mcg (TIO, HandiHaler, Boehringer Ingel-
heim Pharmaceuticals, Inc, Ridgefield, USA) [21] and 
glycopyrronium 50 mcg (GLY, Breezhaler, Novartis, 
Basel, Switzerland) [22]. These studies reported 
additional improvements in trough forced expira-
tory volume in 1  s  (FEV1) at Day 85 of 53 and 33 mL, 
respectively, with UMEC versus the comparators in the 
randomised intent-to-treat (ITT) populations [21, 22]. 
However, limited data are available reporting the rela-
tive cost-effectiveness of UMEC in a clinical setting or 
compared with other once-daily LAMA alternatives. In 
this study, we assessed the cost-effectiveness of UMEC 
monotherapy compared with other once-daily LAMAs 
in patients with COPD from a UK National Health Ser-
vice (NHS) perspective.
Methods
Objectives
Cost-effectiveness analyses were performed comparing 
UMEC with TIO and GLY using data from two GSK clin-
ical trials: analysis 1 compared UMEC with TIO using 
data from GSK Study Number 201316 (NCT02207829); 
[21] analysis 2 compared UMEC with GLY using data 
from GSK Study Number 201315 (NCT02236611) [22]. 
These trials are the only two head-to-head studies of 
these therapies, and therefore constitute the best avail-
able evidence.
Design of the studies included in the analysis
GSK trials 201316 and 201315 were 12-week, multi-
centre, randomised, parallel-group studies performed 
between September 2014 and June 2015 [21, 22]. Eligible 
patients were ≥ 40 years of age with a diagnosis of COPD, 
a smoking history of ≥ 10 pack-years, a modified Medi-
cal Research Council (mMRC) dyspnoea score of ≥ 2, a 
 FEV1/forced vital capacity  (FEV1/FVC) ratio < 0.70 and a 
post-salbutamol  FEV1 ≥ 30% and ≤ 70% of predicted val-
ues [21, 22].
Patients were randomised 1:1 to receive either UMEC 
62.5 mcg via the Ellipta inhaler, or the comparator LAMA 
[TIO 18 mcg, HandiHaler (NCT02207829); GLY 50 mcg, 
Breezhaler (NCT02236611)]. The primary endpoint in 
both trials was non-inferiority in trough  FEV1 at Day 85 
in the per-protocol (PP) populations; other outcomes 
assessed in the ITT populations of both studies included 
trough  FEV1 and trough FVC during the 12-week study 
period, Transition Dyspnoea Index, St George’s Respira-
tory Questionnaire (SGRQ) score, COPD Assessment 
Test score and rescue medication use [21, 22].
UMEC was found to be superior to TIO and non-
inferior to GLY in the PP population; results in the ITT 
population supported these findings (UMEC vs TIO 
difference: 53  mL, 95% confidence interval [CI]: 25, 81; 
p < 0.001; UMEC vs GLY difference: 33  mL, 95% CI: 5, 
61), while effects on patient-reported outcomes and the 
incidence of adverse events were similar between UMEC 
and both comparators [21, 22].
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Cost‑effectiveness model
Cost-effectiveness calculations for both analyses 1 and 2 
were performed using the GALAXY COPD disease pro-
gression model [23]. The model uses a linked risk equa-
tion approach to estimate disease progression, associated 
healthcare costs (e.g. drug costs, cost for hospitalisations 
and outpatient visits), and impact on quality-adjusted life 
years (QALYs) and survival. Statistical risk equations for 
the epidemiological framework and resourcing frame-
work were derived from the Evaluation of COPD Lon-
gitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) [24] and Towards a Revolution in COPD 
Health (TORCH) [25] studies, respectively. Details of 
the model, including internal and external validation, 
have been published previously [23, 26–29]. Disease sta-
tus measures and resource use were computed annually. 
No ethics approval was required for the study as data 
were taken from previously conducted studies that had 
obtained ethical approval.
Study perspective
A UK payer perspective was applied [i.e. the UK National 
Health Service (NHS)] and only direct healthcare costs 
were considered [30].
Model inputs
Population
All analyses were undertaken using data from the ITT 
populations in each trial. To ensure that the compara-
tor arms in the model had the same baseline population 
characteristics, the baseline characteristics were pooled 
across the treatment arms in each trial.
Data on baseline fibrinogen concentrations and base-
line 6-min walk tests (6MWT) were not available from 
studies 201315 and 201316, and these data were esti-
mated using equations developed within the model using 
baseline data from the ECLIPSE study [24]; estimated 
values are presented in Table 1.
Efficacy input parameters
Two measures of treatment efficacy were included in the 
model: between-treatment difference in change from 
baseline in post-bronchodilator  FEV1 at 12  weeks and 
change from baseline in SGRQ score at 12  weeks. The 
values of the model inputs for these efficacy measures are 
presented in Table 1. To avoid double counting of treat-
ment effects (i.e. an overlap of SGRQ impact attribut-
able to  FEV1 improvement and SGRQ impact obtained 
from the clinical trial), input value for SGRQ treatment 
effect was calculated as the difference between SGRQ 
obtained from the clinical trial and SGRQ obtained 
from the model attributable to  FEV1 improvement. This 
ensured that the predicted clinical outcomes matched the 
observed trial data.
Cost input
All costs were based on 2015 Great British Pounds, except 
for drug costs which were based on price lists accessed 
in 2016. Costs of treatment with UMEC (Incruse Ellipta, 
£27.50 per pack), GLY (Seebri Breezehaler, £27.50 per 
pack) and TIO (Spiriva HandiHaler, £34.87 per pack) were 
obtained from the Monthly Index of Medical Specialities 
database [31] (Additional file 1: Table S1) and were esti-
mated for a 30-day supply using dose, pack-size and cost 
per pack. The model inputs for drug costs and resource 
costs are presented in Table 1.
Physician fees and hospital costs were obtained from 
the 2015 Personal Social Services Research Unit [32] 
or the 2014/2015 NHS National Schedule of Reference 
Costs [33]. Resource use included annual count predic-
tions for disease-related general ward days, intensive care 
unit (ICU) days, office visits, day/night home visits, ER 
visits and outpatient visits. These were based on cohort 
baseline parameters and concurrent clinical parameters 
such as exacerbations rates and  FEV1 increment. Using 
the risk equation methodology, the predicted resource 
utilisation counts were multiplied by the relevant unit 
cost for each year of the model. Hospitalisation costs 
were assessed using an estimation of ICU and ward 
day counts. Medication cost index data as of 2016 were 
obtained from the Monthly Index of Medical Speciali-
ties database [34] (Additional file 1: Table S1) and used to 
estimate daily drug costs (Table 1).
Utilities
In each model iteration, SGRQ scores were translated 
into a EuroQol five dimensions questionnaire (EQ-5D 
3L) annual utility estimate using the following relation-
ship [35]:
Model assumptions
Treatment was assumed to continue throughout the 
modelled lifetime time horizon; it was assumed there was 
no waning of treatment effect over time, and no treat-
ment discontinuation was included in the analysis. Treat-
ment effects were assumed to start at 0 months.
EQ − 5D 3L =0.9617− (0.0013 ∗ SGRQ total)
− (0.0001 ∗ [SGRQ total]2)
+ (0.0231 ∗male).
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Table 1 Model inputs: baseline demographics (ITT populations), drug costs and resource costs
Baseline demographics for each treatment arm were pooled in each analysis. Cost data are presented to three significant figures
6MWT 6-min walk test, BMI body mass index, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, ER emergency room, FEV1 forced expiratory 
volume in 1 s, GLY glycopyrronium, ICU intensive care unit, ITT intent-to-treat, Mmrc modified Medical Research Council, NHS National Health Service, SE standard 
error, SGRQ St George’s Respiratory Questionnaire, TIO tiotropium, UMEC umeclidinium
a  Baseline fibrinogen and 6MWT distance were not available in the trial data but were predicted based on risk equations
b  To avoid double-counting of treatment effects an iterative approach was used to adjust the magnitude of the SGRQ treatment effect entered into the model. This 
ensured that the predicted clinical outcomes matched the observed trial data
c  Department of Health, NHS Reference costs 2014–2015 [33]
d  Personal Social Services Research Unit. Unit costs of health & social care [32]
Parameters Analysis 1 (UMEC vs TIO) Analysis 2 (UMEC vs GLY)
Female, % 28.0 32.0
Age (years), mean (SE) 64.2 (0.3) 64.1 (0.3)
BMI, %
 Low 10.0 10.0
 Medium 65.0 61.0
 High 25.0 29.0
Any CVD comorbidity, % 64.0 68.0
Any other comorbidity, % 87.0 89.0
No prior exacerbations at baseline, % 69.0 69.0
mMRC score ≥ 2, % 100.0 100.0
Current smokers, % 51.0 47.0
Height (cm), mean (SE) 169.3 (0.3) 168.8 (0.3)
Number of exacerbations in previous year, mean (SE) 0.42 (0.02) 0.40 (0.02)
Number of severe exacerbations, mean 0.13 0.11
Baseline SGRQ score (units), mean (SE) 45.2 (0.6) 44.7 (0.5)
Derived baseline utility, mean 0.730 0.733
Baseline  FEV1 % predicted, mean (SE) 50.7 (0.3) 50.5 (0.3)
Fibrinogen (mcg/dL), mean (SE)a 459.5 (2.37) 461.5 (2.37)
6MWT distance (m)a 362.9 361.05
Relative treatment effects (UMEC vs comparator)b
 FEV1 increment (mL), mean (SE) 53.0 (14.3) 33.0 (14.3)
 SGRQ change (units), mean (SE) − 0.5 (0.8) − 0.6 (0.8)
Daily drug costs (£)
 UMEC 0.92 0.92
 Reference drug TIO: 1.16 GLY: 0.92
Hospital costs (£)c
 ICU (cost/day) 1260 1260
 General ward (cost/day) 402 402
 COPD-related hospitalisation (cost per episode) 1420 1420
 ER visit (cost per visit) 187 187
 Outpatient visit (initial visit) 199 199
 Outpatient visit (subsequent visit) 147 147
Physician visit costs (£)d
 Day time home visit 128 128
 Night time home visit 128 (assumption) 128 (assumption)
 Visit to physician’s office 65 65
 Telephone consultation 27 27
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Base case settings
A lifetime time horizon was employed as base case due 
to the chronic and progressive nature of COPD and in 
accordance with UK guidelines [30]. Brand costs were 
used for TIO due to the low use of generic TIO in the UK 
(IMS Health, data on file). Costs and benefits were dis-
counted at 3.5% per annum (p.a.) as base case, in accord-
ance with the National Institute for Health and Care 
Excellence (NICE) recommendations [30].
Model outputs
The model estimated: the number of moderate and severe 
exacerbations over time; the exacerbation rate per patient 
per year; total, drug-related and non-drug-related costs; 
the number of life years (LYs) gained (undiscounted); the 
number of QALYs (discounted) gained and associated 
healthcare costs (incremental costs/LY gained, incremen-
tal cost/QALY gained).
Sensitivity and scenario analyses
Scenario analyses were conducted for more limited time 
horizons of 5 and 10 years, discount rates of 0% and 5% 
p.a., and 1- and 3-year durations of treatment. In addi-
tion, scenario analyses were performed for the upper and 
lower 95% confidence limits of  FEV1 increment, SGRQ 
score increment, baseline fibrinogen concentration and 
baseline 6MWT distance, in order to determine the 
impact of these variables on the model results. Scenario 
analyses were also conducted on the price for TIO and a 
threshold analysis was run to determine the price of TIO 
which would lead to the same overall costs for both arms 
in the analysis.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was conducted 
to test the robustness of the results derived from the base 
case analysis and to evaluate the impact of uncertainty 
in the parameters used within the model. This was con-
ducted by assigning distributions to input parameters 
and randomly sampling from these distributions over 
1000 Monte Carlo simulations. A normal distribution 
was used for treatment effects and risk equations were 
derived using correlated draws from a Cholesky decom-
position table obtained from the covariance matrices for 
each equation. The outputs of this analysis were summa-
rised in scatter plots of incremental costs and effective-
ness, and net benefit acceptability curves (NBAC) for 
competing treatments included in the model.
Results
Comparison of UMEC with TIO
In the lifetime analysis, estimated total accumulated 
costs were £12,300 and £12,800 for UMEC and TIO 
respectively (Table  2). UMEC provided an additional 
0.195 LYs and 0.118 QALYs compared with TIO, with 
cost savings of £460 (Table  2). Patients on UMEC also 
had fewer exacerbations per patient per year (0.718) 
compared with TIO (0.740) (Table  2). Despite higher 
healthcare costs with UMEC, reflecting increased sur-
vival times, there were overall cost savings due to the 
lower drug costs of UMEC compared with TIO. UMEC 
therefore dominated TIO, providing both improved out-
comes and cost savings.
Results were similar in the analyses with 5- and 10-year 
horizons, with UMEC showing improved outcomes 
(0.018 and 0.082 LYs; 0.029 and 0.072 QALYs, respec-
tively) and cost savings compared with TIO (£355 and 
£486, respectively) (Additional file 1: Tables S2 and S3).
In the PSA, UMEC was less costly than TIO, and 
achieved a greater gain in QALYS than TIO, in 100% 
of the simulations in the cost-effectiveness scatter plot 
(Fig.  1a). The NBAC (Additional file  1: Figure S1A) 
showed that UMEC generated higher net monetary ben-
efit in all simulations.
In the scenario analyses, UMEC continued to dominate 
TIO across most scenarios (Additional file  1: Table  S4). 
However, in three scenarios, UMEC did not dominate 
TIO: the scenario in which SGRQ upper confidence 
limit was tested [incremental cost-effectiveness ratio 
(ICER) = £64,500/QALY], the scenario using generic 
costs for TIO (£25.80 per pack, ICER = £3130/QALY), 
and the scenario in which the cost of TIO was assumed 
to be same as UMEC (ICER = £1810/QALY). Threshold 
analyses were performed to determine the price for TIO 
which would lead to the same overall costs for both arms 
in the analyses. This price was identified as £29.83 for 30 
inhalations, therefore if TIO was priced lower than this 
value, UMEC would no longer be dominant.
Comparison of UMEC with GLY
In the lifetime analysis, estimated total accumulated 
costs were £12,000 and £11,800 for UMEC and GLY 
respectively (Table 2). Against similar drug costs, UMEC 
provided an additional 0.124 LYs and 0.101 QALYs com-
pared with GLY, with an additional incremental cost of 
£132 (Table  2). The estimated ICER was £1070/LY and 
£1310/QALY gained. Patients on UMEC also had fewer 
exacerbations per patient per year (0.726) compared with 
GLY (0.740) (Table  2). However, all costs were higher 
with UMEC compared with GLY.
Results were similar in the analyses with 5- and 10-year 
horizons, with UMEC showing improved outcomes 
(0.012 and 0.052 LYs; 0.032 and 0.068 QALYs, respec-
tively) and higher costs (£14 and £61 respectively) com-
pared with GLY (Additional file 1: Tables S2 and S3).
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Results of the PSA showed that out of 1000 simulations, 
95% resulted in an ICER/QALY of £284–£2060 (Fig. 1b). 
The NBAC (Additional file  1: Figure S1B) showed that 
UMEC generated higher net monetary benefit in all sim-
ulations above a willingness-to-pay threshold of £5000 
per additional QALY.
In the scenario analyses, results remained consistent 
with the base case analysis (Additional file  1: Table  S4), 
except for the SGRQ upper confidence limit: in this sce-
nario, the reduction in SGRQ for UMEC was lower than 
for GLY, hence this scenario resulted in UMEC being 
dominated by GLY. ICERs for other scenarios ranged 
from £113/QALY (duration of treatment = 1  year) to 
£1670/QALY  (FEV1 upper confidence limit). The esti-
mated ICERs were £1430/QALY and £1260/QALY for 
costs and benefit discount rates of 0% and 5% p.a., respec-
tively. The analyses were most sensitive to time horizon, 
duration of treatment effect, change in SGRQ score and 
 FEV1 increment.
Discussion
This study showed that UMEC provided gains in LYs and 
QALYs, and numerical reductions in moderate and severe 
exacerbation rates, compared with both TIO and GLY. 
The lifetime analysis demonstrated that UMEC domi-
nated TIO, providing improved outcomes with reduced 
treatment and resource costs. This dominance was main-
tained when a 5- and 10-year horizon was employed, and 
across several scenario analyses. However, when price 
parity was applied, UMEC no longer dominated TIO, 
with an ICER of £1810/QALY. Results of the scenario 
analyses showed the model was most sensitive to scenar-
ios in which the duration of treatment was 1 or 3 years, 
and SGRQ change, while the model was relatively insen-
sitive to discount rate and upper confidence limits for 
 FEV1 increment, 6MWT and fibrinogen data. In compari-
son with GLY, results obtained from the lifetime horizon 
showed that costs associated with UMEC were higher. 
Table 2 Model results: lifetime horizon
Cost and cost-effectiveness data are presented to three significant figures for values of three figures or more, and to the nearest pound for values rounding to less 
than 100
CI confidence interval, GLY glycopyrronium, ICER incremental cost-effectiveness ratio, LY life year, PPPY per person per year, QALY quality-adjusted life year, TIO 
tiotropium, UMEC umeclidinium
Analysis 1 (UMEC vs TIO) Analysis 2 (UMEC vs GLY)
TIO UMEC GLY UMEC
Cumulative number of exacerbations
 Moderate 4.926 4.924 4.952 4.951
 Severe 1.659 1.608 1.636 1.604
 TOTAL 6.585 6.532 6.588 6.555
 Severe exacerbations PPPY 0.186 0.177 0.184 0.178
 Total exacerbations PPPY 0.740 0.718 0.740 0.726
Outcomes
 Accumulated LYs (undiscounted) 8.902 9.097 8.906 9.029
 Accumulated QALYs 5.003 5.121 5.038 5.139
Costs
 Accumulated costs (total) £12,800 £12,300 £11,800 £12,000
 Drug costs £3180 £2560 £2510 £2540
 Non-drug costs £9590 £9760 £9310 £9420
 Hospital costs £8800 £8960 £8550 £8640
 Outpatient/hospital/clinic costs £504 £514 £480 £486
 Physician visits (office, home, day or 
night)
£288 £292 £288 £290
Incremental results (95% CI), UMEC vs comparator
 Incremental exacerbations − 0.053 (− 0.171, 0.028) − 0.033 (− 0.135, 0.017)
 Incremental cost − £460 (− £645, − £240) £132 (£12, £330)
 Incremental LYs 0.195 (0.069, 0.356) 0.124 (0.015, 0.281)
 Incremental QALYs 0.118 (0.055, 0.191) 0.101 (0.043, 0.179)
 ICER (QALY) Dominant £1310 (£284, £2060)
 ICER (LY) Dominant £1070 (£718, £1520)
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This could be attributed to the increased drug costs, as 
well as to the survival benefit associated with UMEC, as 
patients remained in the model for longer and therefore 
incurred increased treatment and resource costs. These 
results were generally consistent across other time hori-
zons and scenario analyses. Nevertheless, UMEC was 
shown to be cost-effective compared with GLY in most 
scenarios, with cost-effectiveness falling well below the 
willingness-to-pay threshold of £20,000–30,000 per 
QALY set by the NICE guidelines [36].
Data comparing cost-effectiveness of different LAMA 
monotherapies are scarce. One study compared the cost-
effectiveness of TIO with GLY in Sweden [37], and one 
study compared the cost-effectiveness of these treatment 
in Canada, Spain, Sweden and the UK [38, 39]. In the for-
mer study, GLY was found to be less costly and more effec-
tive than TIO as maintenance treatment for patients with 
moderate to severe COPD in Sweden [37]. In the latter 
study, TIO generated improved outcomes compared with 
GLY in all countries, and was cost-saving compared with 
GLY in Canada and the UK. Costs per QALY were posi-
tive for Spain and Sweden; however, the estimated ICERs 
remained below the respective willingness-to-pay thresh-
olds for each country [38]. The outcomes from this latter 
study contrast with the results of the current cost-effec-
tiveness analysis. Possible reasons for this could include 
the use of different efficacy parameters, such as the assess-
ment of treatment efficacy including exacerbation rates in 
the multi-country study. It is also likely that the relative 
costs of the different drugs in each country would drive 
the differences in the cost-effectiveness. Additionally, the 
multi-country study included data from patients with very 
severe COPD, while this study excluded such patients who 
would not be ideal candidates for LAMA monotherapy in 
accordance with the GOLD 2017 COPD strategy report 
[40, 41]. An additional advantage of the model used in the 
current study was that it could integrate multiple factors 
affecting outcomes in COPD to predict disease progres-
sion and economic outcomes [23]. This may enable more 
accurate predictions than other models commonly used in 
cost-effectiveness analyses that are based only upon dis-
ease progression, with disease severity classified according 
to measurements of percentage predicted  FEV1 [42].
The efficacy inputs used for this study are based on 
bronchodilation, as measured by  FEV1 [21, 22]. Improve-
ments in lung function measured by increased  FEV1 can 
result in better health outcomes and lower COPD exac-
erbation risk over a longer period [21, 22, 43], and may 
be responsible for the larger treatment effect observed 
on the cumulative number of severe versus moderate 
exacerbations. However, the use of a LAMA as mono-
therapy is not common, as a large proportion of patients 
with COPD will step-up to dual bronchodilator therapy 
with a LAMA/LABA or the combination of a LAMA 
with inhaled corticosteroid (ICS)/LABA. Studies have 
shown greater improvements in trough  FEV1 when using 
a dual LABA/LAMA therapy compared to LAMA mono-
therapy. A recent systematic review and meta-analysis 
compared the efficacy and safety of LABA/LAMA with 
LAMA or ICS/LABA in adults with moderate to severe 
COPD and found that the LAMA/LABA combinations 
provided greater improvements in trough  FEV1 than 
LAMA monotherapy [44]. Studies using UMEC in com-
bination with the LABA vilanterol 25  mcg (VI) showed 
a clinically meaningful and significant improvement in 
trough  FEV1 versus TIO [45]. UMEC/VI was also found 
to be potentially cost-effective compared with TIO, with 
an ICER of €21,475/QALY [46]. Although triple therapies 
have shown to improve lung function and quality of life 
compared to ICS/LABA [47], data on the cost-effective-
ness of triple therapy in patients with COPD are lacking.
As the studies included in the model lacked data on 
baseline fibrinogen concentrations and 6MWT distances, 
these were estimated using predictive equations within 
the model. Scenario analyses with variable lower and 
upper confidence limit values for both variables showed 
minimal changes in the overall results. Nevertheless, it 
would be highly recommended to collect these variables 
in future studies for which analysis may be performed 
using the current model.
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At this moment, there are no trials providing data on 
the use of LAMA therapy for a longer duration than the 
scenario analyses ran in the current study (5, 10  years 
and lifetime). Therefore, we needed to make assump-
tions in order to run the analyses for these scenarios. One 
of the assumptions was to maintain treatment effects 
without waning until the end of the year. This assump-
tion was supported by data from the studies included in 
the model, demonstrating a rapid response to treatment 
that was stable over the last 2 months of the assessment 
periods [21, 22]. In addition, data from the Understand-
ing Potential Long-Term Impacts on Function with Tio-
tropium (UPLIFT) trial investigating the use of LAMA 
therapy over a 4-year period did not show a decline in 
treatment effect over time. Indeed, sustained improve-
ments were observed on several outcomes in addition 
to lung function, such as HRQoL, risk of exacerbations, 
exacerbation-related hospitalisations and reductions in 
respiratory and cardiac associated morbidity [40].
Due to the chronic and progressive nature of COPD, 
and in accordance with UK guidance for the conduct 
of economic evaluations [30], a lifetime horizon was 
employed. No suitable data could be identified to esti-
mate treatment discontinuation or switch rates for the 
analyses presented. Therefore, another assumption was 
made within the model: that patients did not discontinue 
or switch their treatment. In reality, stability of treatment 
is unlikely, as patients will usually escalate from LAMA 
monotherapy to combined therapies, especially as their 
disease progresses, in accordance with treatment recom-
mendations [2]. However, the efficacy of LAMA ther-
apy is not expected to be diminished in these scenarios. 
Indeed, recently published data indicate that efficacy dif-
ferences between LAMA therapies are still present when 
administered as part of dual LAMA/LABA combination 
therapies [48]. Our approach is therefore a conservative 
estimate; however, we believe that based on the available 
data this was the most appropriate approach. In a similar 
vein, the model was built upon the assumption that treat-
ment continued within each modelled time horizon (i.e. 
over a lifetime horizon, a 10-year horizon and a 5-year 
horizon). As such, costs and effects were built upon the 
assumption of patient adherence over each time hori-
zon. The model is therefore not necessarily built to reflect 
treatment changes as the disease progresses in each indi-
vidual patient.
Conclusions
For treatment of patients with COPD in the UK, over a 
lifetime horizon, treatment with UMEC dominates treat-
ment with TIO. In comparison with GLY, treatment 
with UMEC achieved improved outcomes with fewer 
exacerbations; however, treatment and resource costs 
were higher due to the higher drug costs and increased 
survival time. UMEC can therefore be considered a 
dominant treatment option compared to TIO and a cost-
effective treatment option compared to GLY. These data 
may aid payers in making judgements on which LAMA 
treatments can be considered cost-effective in a UK 
setting.
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